Who owns Tango Therapeutics Inc?

The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA. TNGX | Complete Tango Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

What is the target price for Tango Therapeutics (tngx)?

1 Wall Street analysts have issued 1-year target prices for Tango Therapeutics' shares. Their TNGX share price forecasts range from $16.00 to $21.00. On average, they expect the company's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 178.2% from the stock's current price.

Is Tango Therapeutics a good buy?

Tango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts' consensus price target of $18.50, Tango Therapeutics has a forecasted upside of 178.2% from its current price of $6.65.